United-Guardian, Inc. (UG) reported a significant decline in its 2025 financial results, with net sales falling 13% year-over-year to $10.55 million, down from $12.18 million. Net income also dropped approximately 35%, from $3.25 million to $2.11 million, while earnings per share decreased to 46 cents from 71 cents. The company’s stock has gained 6.3% post-earnings, contrasting with a 1.7% decline in the S&P 500.
The downturn was attributed to reduced demand in the cosmetic ingredients segment, affected by high distributor inventory and global softness, especially in China. Concurrently, pharmaceutical product sales increased by 15%, partly offsetting losses. Total assets decreased to $13.11 million at the end of 2025 from $13.80 million in 2024, while operating income contracted to $2.24 million from $3.65 million.
Looking ahead, management is optimistic about regaining market share and improving sales through new marketing strategies and distribution agreements. Recent approvals from two major pharmacy benefit managers are expected to enhance access and support long-term growth in the pharmaceutical sector.
